Literature DB >> 19738075

Advances in Ewing's sarcoma research: where are we now and what lies ahead?

José Luis Ordóñez1, Daniel Osuna, David Herrero, Enrique de Alava, Juan Madoz-Gúrpide.   

Abstract

Ewing's sarcoma family tumors (EFT) are characterized by specific chromosomal translocations, which lead to EWS/ETS transcription factors. Elucidation of EWS/ETS target gene networks within the context of other signaling pathways, together with the identification of the initiating cell, and the development of genetically engineered mice will hopefully lead to biology-based therapeutic strategies for these tumors.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19738075     DOI： 10.1158/0008-5472.CAN-08-4041

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  Cancer: Oncogenes in context.

Authors:  Michael C Heinrich; Christopher L Corless
Journal:  Nature       Date:  2010-10-14       Impact factor: 49.962

Review 3.  Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.

Authors:  Valerie B Sampson; Davida F Kamara; E Anders Kolb
Journal:  Expert Opin Drug Discov       Date:  2013-07-12       Impact factor: 6.098

4.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.

Authors:  Nicolò Riggi; Mario-Luca Suvà; Claudio De Vito; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Luisa Cironi; Michalina Janiszewska; Tanja Petricevic; Domizio Suvà; Stéphane Tercier; Jean-Marc Joseph; Louis Guillou; Ivan Stamenkovic
Journal:  Genes Dev       Date:  2010-04-09       Impact factor: 11.361

5.  Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.

Authors:  Pilar Puerto-Camacho; Ana Teresa Amaral; Salah-Eddine Lamhamedi-Cherradi; Joseph A Ludwig; Enrique de Álava; Brian A Menegaz; Helena Castillo-Ecija; José Luis Ordóñez; Saioa Domínguez; Carmen Jordan-Perez; Juan Diaz-Martin; Laura Romero-Pérez; Maria Lopez-Alvarez; Gema Civantos-Jubera; María José Robles-Frías; Michele Biscuola; Cristina Ferrer; Jaume Mora; Branko Cuglievan; Keri Schadler; Oliver Seifert; Roland Kontermann; Klaus Pfizenmaier; Laureano Simón; Myriam Fabre; Ángel M Carcaboso
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

6.  RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Authors:  Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer       Date:  2010-08-18       Impact factor: 27.401

7.  Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma.

Authors:  Patrick P Lin; Yongxing Wang; Guillermina Lozano
Journal:  Sarcoma       Date:  2010-10-05

8.  Outcome of multimodality treatment of Ewing's sarcoma of the extremities.

Authors:  Akshay Tiwari; Himesh Gupta; Sandeep Jain; Gauri Kapoor
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

9.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31

10.  Ewing's sarcoma: overcoming the therapeutic plateau.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Discov Med       Date:  2012-06       Impact factor: 2.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.